Literature DB >> 8937710

The effects of SB 216469, an antagonist which discriminates between the alpha 1A-adrenoceptor and the human prostatic alpha 1-adrenoceptor.

R Chess-Williams1, C R Chapple, F Verfurth, A J Noble, C J Couldwell, M C Michel.   

Abstract

1. The affinity of the alpha 1-adrenoceptor antagonist SB 216469 (also known as REC 15/2739) has been determined at native and cloned alpha 1-adrenoceptor subtypes by radioligand binding and at functional alpha 1-adrenoceptor subtypes in isolated tissues. 2. In radioligand binding studies with [3H]-prazosin, SB 216469 had a high affinity at the alpha 1A-adrenoceptors of the rat cerebral cortex and kidney (9.5-9.8) but a lower affinity at the alpha 1B-adrenoceptors of the rat spleen and liver (7.7-8.2). 3. At cloned rat alpha 1-adrenoceptor subtypes transiently expressed in COS-1 cells and also at cloned human alpha 1-adrenoceptor subtypes stably transfected in Rat-1 cells, SB 216469 exhibited a high affinity at the alpha 1a-adrenoceptors (9.6-10.4) with a significantly lower affinity at the alpha 1b-adrenoceptor (8.0-8.4) and an intermediate affinity at the alpha 1d-adrenoceptor (8.7-9.2). 4. At functional alpha 1-adrenoceptors, SB 216469 had a similar pharmacological profile, with a high affinity at the alpha 1A-adrenoceptors of the rat vas deferens and anococcygeus muscle (pA2 = 9.5-10.0), a low affinity at the alpha 1B-adrenoceptors of the rat spleen (6.7) and guinea-pig aorta (8.0), and an intermediate affinity at the alpha 1D-adrenoceptors of the rat aorta (8.8). 5. Several recent studies have concluded that the alpha 1-adrenoceptor present in the human prostate has the pharmacological characteristics of the alpha 1A-adrenoceptor subtype. However, the affinity of SB 216469 at human prostatic alpha 1-adrenoceptors (pA2 = 8.1) determined in isolated tissue strips, was significantly lower than the values obtained at either the cloned alpha 1a-adrenoceptors (human, rat, bovine) or the native alpha 1A-adrenoceptors in radioligand binding and functional studies in the rat. 6. Our results with SB 216469, therefore, suggest that the alpha 1-adrenoceptor mediating contractile responses of the human prostate has properties which distinguish it from the cloned alpha 1a-adrenoceptor or native alpha 1A-adrenoceptor. Since it has previously been shown that the receptor is not the alpha 1B- or alpha 1D-adrenoceptor, the functional alpha 1-adrenoceptor of the human prostate may represent a novel receptor with properties which differ from any of the alpha 1-adrenoceptors currently defined by pharmacological means.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8937710      PMCID: PMC1915881          DOI: 10.1111/j.1476-5381.1996.tb16009.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  30 in total

Review 1.  Benign prostatic hyperplasia. Medical and minimally invasive treatment options.

Authors:  J E Oesterling
Journal:  N Engl J Med       Date:  1995-01-12       Impact factor: 91.245

2.  Cloning, functional expression and tissue distribution of human alpha 1c-adrenoceptor splice variants.

Authors:  A Hirasawa; K Shibata; K Horie; Y Takei; K Obika; T Tanaka; N Muramoto; K Takagaki; J Yano; G Tsujimoto
Journal:  FEBS Lett       Date:  1995-04-24       Impact factor: 4.124

3.  Identification of alpha 1-adrenoceptor subtypes present in the human prostate.

Authors:  C Faure; C Pimoule; G Vallancien; S Z Langer; D Graham
Journal:  Life Sci       Date:  1994       Impact factor: 5.037

4.  Cloning, expression, and tissue distribution of the rat homolog of the bovine alpha 1C-adrenergic receptor provide evidence for its classification as the alpha 1A subtype.

Authors:  D M Perez; M T Piascik; N Malik; R Gaivin; R M Graham
Journal:  Mol Pharmacol       Date:  1994-11       Impact factor: 4.436

5.  Characterization of alpha-1 adrenoceptor subtypes in human and canine prostate membranes.

Authors:  A S Goetz; M W Lutz; T J Rimele; D L Saussy
Journal:  J Pharmacol Exp Ther       Date:  1994-12       Impact factor: 4.030

6.  The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype.

Authors:  C Forray; J A Bard; J M Wetzel; G Chiu; E Shapiro; R Tang; H Lepor; P R Hartig; R L Weinshank; T A Branchek
Journal:  Mol Pharmacol       Date:  1994-04       Impact factor: 4.436

7.  Comparison of cloned and pharmacologically defined rat tissue alpha 1-adrenoceptor subtypes.

Authors:  M C Michel; P A Insel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-08       Impact factor: 3.000

8.  Pharmacological evidence of distinct alpha 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery.

Authors:  A Hatano; H Takahashi; M Tamaki; T Komeyama; T Koizumi; M Takeda
Journal:  Br J Pharmacol       Date:  1994-11       Impact factor: 8.739

9.  Cloning and pharmacological characterization of human alpha-1 adrenergic receptors: sequence corrections and direct comparison with other species homologues.

Authors:  D A Schwinn; G I Johnston; S O Page; M J Mosley; K H Wilson; N P Worman; S Campbell; M D Fidock; L M Furness; D J Parry-Smith
Journal:  J Pharmacol Exp Ther       Date:  1995-01       Impact factor: 4.030

10.  Alpha 1-adrenoceptor subtypes in the human prostate.

Authors:  C R Chapple; R P Burt; P O Andersson; P Greengrass; M Wyllie; I Marshall
Journal:  Br J Urol       Date:  1994-11
View more
  6 in total

1.  Investigation of the subtypes of alpha1-adrenoceptor mediating contractions of rat vas deferens.

Authors:  V Honner; J R Docherty
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

2.  Discrimination by SZL49 between contractions evoked by noradrenaline in longitudinal and circular muscle of human vas deferens.

Authors:  Nnaemeka I B Amobi; John Guillebaud; A V Kaisary; Eileen Turner; I Christopher H Smith
Journal:  Br J Pharmacol       Date:  2002-05       Impact factor: 8.739

Review 3.  What makes the α1A -adrenoceptor gene product assume an α1L -adrenoceptor phenotype?

Authors:  Carl W White; Edilson Dantas da Silva Junior; Linzi Lim; Sabatino Ventura
Journal:  Br J Pharmacol       Date:  2019-03-27       Impact factor: 8.739

4.  Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics.

Authors:  K Taguchi; R F Schäfers; M C Michel
Journal:  Br J Clin Pharmacol       Date:  1998-01       Impact factor: 4.335

Review 5.  Phenotype pharmacology of lower urinary tract α(1)-adrenoceptors.

Authors:  A Nishimune; H Yoshiki; J Uwada; A S M Anisuzzaman; H Umada; I Muramatsu
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 6.  Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate.

Authors:  Martin C Michel; Wim Vrydag
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.